文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

重复立体定向放疗治疗多发性脑转移的预后评分验证:CYBER-SPACE随机Ⅱ期试验二次分析

Prognostic scores for patients with multiple brain metastases treated with repeated stereotactic radiosurgery - a secondary analysis of the CYBER-SPACE randomized phase 2 trial.
PubMed 文献 · Radiother Oncol · 2025-11-11

该研究基于CYBER-SPACE随机Ⅱ期试验的202例接受 upfront 和重复SRS(最多10个同时脑转移)的患者,评估多种传统预后评分在当代系统治疗背景下的预测价值。结果显示,黑色素瘤dsGPA和BMV评分可同时预测总生存(OS)和WBRT指征(WBRTi),BSBM仅预测OS;BMV是唯一在所有肿瘤类型中均能预测两个终点的评分,并识别出两个终点特异性BMV截断值。

要点

  • BMV评分是唯一在所有肿瘤类型中同时预测OS和WBRTi的评分。
  • 黑色素瘤dsGPA可预测OS(p=0.014)和WBRTi(p=0.042)。
  • BSBM仅预测OS(p=0.0011),BMV预后价值持续至第四次复发。

核心结论

  • BMV是唯一能在所有肿瘤类型中同时预测OS和WBRTi的评分。
  • 两个终点特异性BMV截断值可能辅助临床在继续SRS与早期WBRT之间决策,但需外部验证。

研究设计与样本

  • CYBER-SPACE随机Ⅱ期试验的二次分析,共纳入202例接受 upfront 和重复SRS(最多10个同时脑转移)的患者。
  • 评估RPA、M-RPA、GPA、dsGPA、lung-mol GPA、BSBM、SIR和BMV评分对OS和WBRTi的预测价值。
  • BMV评分在第1至第4次远处脑失败(DBF)时计算,采用Kaplan-Meier分析和log-rank检验。

主要发现

  • 常见原发肿瘤为非小细胞肺癌(63%)、黑色素瘤(16%)和乳腺癌(10%)。
  • 初始SRS后中位OS为13.1个月(Q1-Q3:5.2-45.0)。
  • 24个月时40例(20.8%)达到WBRTi。
  • 黑色素瘤dsGPA预测OS(p=0.014)和WBRTi(p=0.042),BSBM仅预测OS(p=0.0011)。
  • BMV预测OS和WBRTi(均p<0.0001),且预后价值持续至第四次复发。

关键数值与推荐

  • WBRTi定义为同时脑转移>10个或软脑膜疾病。
  • 识别出两个终点特异性BMV截断值,分别区分生存和WBRTi的两个预后组(p<0.0001)。

临床怎么用

  • 在系统治疗时代,BMV评分可用于同时评估OS和WBRTi风险,辅助选择继续SRS或早期WBRT。
  • 黑色素瘤患者可参考dsGPA预测OS和WBRTi,BSBM可辅助预测OS。

局限性

  • BMV截断值需进一步外部验证。
  • 本文为二次分析,部分评分预测价值有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic radiosurgery (SRS) is frequently combined with modern systemic therapy for brain metastases (BM). Most established prognostic scores were developed from historical cohorts and may not reflect current treatment standards. The randomized phase II CYBER-SPACE trial investigated upfront and repeated SRS for up to ten simultaneous BMs during systemic therapy, aiming to avoid whole-brain radiotherapy (WBRT). This secondary analysis evaluates the validity of established scores in this contemporary cohort. METHODS: Assessed scores included the Recursive Partitioning Analysis (RPA), modified RPA (M-RPA), Graded Prognostic Assessment (GPA), diagnosis-specific GPA (dsGPA), lung-mol GPA, Basic Score for Brain Metastases (BSBM), Score Index for Radiosurgery (SIR), and Brain Metastasis Velocity (BMV) score. Their predictive value for overall survival (OS) and WBRT indication (WBRTi; defined as > 10 simultaneous BMs or leptomeningeal disease) was analysed. The BMV score was calculated at first through fourth distant brain failure (DBF). Kaplan-Meier analyses and log-rank tests were used. RESULTS: A total of 202 patients were enrolled. Common primary tumors were non-small cell lung cancer (63 %), melanoma (16 %), and breast cancer (10 %). Median OS after initial SRS was 13.1 months (Q1-Q3: 5.2-45.0). At 24 months, 40 patients (20.8 %) reached WBRTi. The dsGPA for melanoma (OS: p = 0.014; WBRTi: p = 0.042) and BMV (OS and WBRTi: p < 0.0001) were predictive for both endpoints; BSBM was predictive for OS only (p = 0.0011). The BMV remained prognostic through the fourth recurrence. Two endpoint-specific BMV cut-offs were identified, separating two prognostic groups for survival and WBRTi, respectively (p < 0.0001). CONCLUSION: BMV was the only score able to predict both OS and WBRTi across all tumor types. Two distinct endpoint-specific BMV cut-offs may support clinical decision-making between continued SRS and early WBRT, but warrant further external validation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Schiele A, Bernhardt D, Welzel T, et al. Prognostic scores for patients with multiple brain metastases treated with repeated stereotactic radiosurgery - a secondary analysis of the CYBER-SPACE randomized phase 2 trial. Radiother Oncol. 2025. PMID: 41232776. doi:10.1016/j.radonc.2025.111279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。